Continuing Medical Education Program - The Medical Letter

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for health care professionals (primarily physicians and pharmacists) to keep up to date with new drugs that are approved by the FDA, as well as keep up with the standard of care treatments for specific indications. Specifically, the content of The Medical Letter Continuing Medical Education Program covers the mechanisms of action, pharmacokinetics, clinical trials, adverse effects, interactions, dosages and routes of administration of the drugs discussed. Participants are required to answer exam questions based on the content of The Medical Letter. Importantly, the objectives of developing the content on which the exam is based are to educate the participant, impact clinical practice and improve patient outcomes. The Medical Letter's unbiased content is free of commercial influence and financial sponsorship. The Medical Letter does not accept advertising, grants or donations. The program is completely funded by fees paid by the exam participants. The Medical Letter Continuing Medical Education program is accredited by: ACCME AAFP ACPE.

You may earn up to 26 credits per year, by choosing one of the following:

	FREE Individual Exams – Freely available only to active subscribers of The Medical Letter. Answer six questions per issue and submit answers online. Earn one credit/exam. 1 credit/exam Subscribe now

	Comprehensive Exam – Available online or in print to Medical Letter subscribers, this 78 question test enables you to earn 13 AMA PRA Category 1 credits immediately with the successful completion of the test. Take the exam online and receive your Continuing Medical Education certificate within 3 business days! Our Comprehensive exams allow you to test at your own pace in the comfort of your home or office. Save airfare, conference expenses and time away from your practice. Comprehensive tests are offered every January and July enabling you to earn up to 26 credits per year. Order using the form below. $44.50/13 credits Subscribe now

	Purchase Individual Exams – Available to non-subscribers. Access content and answer six questions, online only, for any available issue and earn one credit. Order using the form below. 1 credit/exam; $12.00/credit

The Medical Letter Individual Exams — Online Only

I would like to order the following Online Per Issue Individual Exams eligible for 1 credit each:

$12
per exam

	1365 Dexmedetomidine (Precedex) for ICU Sedation; Capsaicin Patch (Qutenza) for Postherpetic Neuralgia; New Treatments for Keratoconus Expires 05/30/2012
	1366 Belimumab (Benlysta) for Systemic Lupus Erythematosus; Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect; Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer Expires 06/13/2012
	1367 Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes; Spinosad (Natroba) Topical Suspension for Head Lice; Ipilimumab (Yervoy) for Metastatic Melanoma
	1368 Vilazodone (Viibryd) - A New Antidepressant; Testosterone Topical Solution (Axiron) for Hypogonadism; Levofloxacin Revisited
	1369 Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C; Roflumilast (Daliresp) for COPD
	1370 New Simvastatin Dosing Recommendations; Extended-Release Hydromorphone (Exalgo) For Pain; Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
	1371 Rivaroxaban (Xarelto) for Prevention of Venous Thromboembolism; Rilpivirine (Edurant) - A New Drug for HIV Infection
	1372 Ticagrelor (Brilinta) - Better Than Clopidogrel (Plavix)?; Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome; Screening for Melanoma
	1373 Fidaxomicin (Dificid) for Clostridium Difficile Infection; Adjunctive Antipsychotics for Major Depression; Peginterferon Alfa-2b (Sylatron) for Melanoma
	1374 Vemurafenib (Zelboraf) for Metastatic Melanoma; Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding; Quetiapine (Seroquel) and QT-Interval Prolongation
	1375 Influenza Vaccine for 2011-2012; Do Calcium Supplements Increase the Risk of Myocardial Infarction?; Propofol Revisited
	1376 A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis); Drugs for Ovulation Induction
	1377 Sitagliptin and Simvastatin (Juvisync); Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia; Vasopressors and Inotropes
	1378 What about Niacin?; Once-Daily Gabapentin (Gralise) for Postherpetic Neuralgia; Vaccines and Pregnancy
	1379 Rivaroxaban (Xarelto) for Acute Coronary Syndrome; Bleeding with Dabigatran (Pradaxa); Belatacept (Nulojix) for Prevention of Renal Transplant Rejection
	1380 Fentanyl Nasal Spray (Lazanda)) for Pain; Who Should Take Vitamin Supplements?; Safety of Dronedarone (Multaq)
	1381 Antiviral Drugs for Influenza; Vandetanib (Caprelsa) for Medullary Thyroid Cancer
	1382 Epidural Corticosteroid Injections for Lumbar and Cervical Radiculopathy; Beta-Adrenergic Blockers and Breast Cancer; Intranasal Ketorolac (Sprix)
	1383 Aflibercept (Eylea) for Age-Related Macular Degeneration; PDE5 Inhibitors for Erectile Dysfunction; Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
	1384 Salt Restriction; Zolpidem Oral Spray (Zolpimist) for Insomnia; Deferiprone (Ferriprox) for Iron Overload
	1385 Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension; Clobazam (Onfi) for Lennox-Gastaut Syndrome; Glucarpidase (Voraxaze) for Methotrexate Toxicity
	1386 Statin Label Changes; Extended-Release Exenatide (Bydureon) for Type 2 Diabetes; Nitroglycerin Ointment (Rectiv) for Anal Fissure
	1387 Low-Dose Sublingual Zolpidem (Intermezzo) for Insomnia due to Middle-of-the-Night Awakening; Bupivacaine Liposome Injection (Exparel) for Postsurgical Pain; Ruxolitinib (Jakafi) for Myelofibrosis
	1388 Ivacaftor (Kalydeco) for Cystic Fibrosis; Transcatheter Aortic-Valve Replacement; Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
	1389 Indacaterol (Arcapta Neohaler) for COPD; Ingenol Mebutate (Picato) for Actinic Keratoses
	1390 Off-Label Use of Ketorolac for Athletic Injuries; Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes; Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain

ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 26 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This Continuing Medical Education (CME) activity was planned and produced in accordance with the ACCME Essentials and Policies.

AAFP This Enduring Material activity, The Medical Letter Continuing Medical Education Program, has been reviewed and is acceptable for up to 26 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins January 1, 2012. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Council on Pharmacy Education

The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.